Form 4: Passage Bio Director Awarded Stock Options

Athena Countouriotis, a director at Passage Bio, Inc., was granted stock options to purchase 47,693 shares of common stock on May 21, 2024.

Summary

• On May 21, 2024, Athena Countouriotis, a director of Passage Bio, Inc., received stock options for 47,693 shares.
• The exercise price of these options is $1.28 per share.
• The options vest on the earlier of May 21, 2025, or the date of the company's 2025 Annual Meeting, contingent upon continuous service to the issuer.
• The options expire on May 21, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine grant of stock options to a director, which is a common practice. It doesn't inherently indicate positive or negative performance.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize directors and align their interests with the long-term success of the company. This is especially true for companies like Passage Bio, which are focused on research and development and require strong leadership to navigate the challenges of drug development.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the biotech industry.
• The size of the grant (47,693 shares) would need to be compared to grants made by peer companies of similar market capitalization and stage of development to determine if it is within industry norms.
• Companies like BioMarin Pharmaceutical and Sarepta Therapeutics also use stock options as part of their compensation packages for directors and executives.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the director's performance leads to company growth.
• Employees may be indirectly impacted by the director's decisions and contributions to the company.

Key Dates